Table 1.

Neoadjuvant Chemotherapy and Response Rates for Inflammatory Breast Cancer

Hance KW, Anderson WF, Devesa SS, et al. Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results program at the National Cancer Institute. J Natl Cancer Inst 2005;97:966–975.
Lee B, Tannenbaum N. Inflammatory carcinoma of the breast: a report of twenty-eight cases from the breast clinic of memorial hospital. Surg Gynecol Obstet 1924;38:580.
Haagensen CD. Diseases of the female breast. Trans N Engl Obstet Gynecol Soc 1956;10:141–156.
Walshe JM, Swain SM. Clinical aspects of inflammatory breast cancer. Breast Dis 2005;22:35–44.
Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992;10:1014–1024.
Chang S, Parker SL, Pham T, et al. Inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results program of the National Cancer Institute, 1975–1992. Cancer 1998;82:2366–2372.
Greene FL, Page DL, Fleming ID, et al. Breast. In: Greene FL, Page DL, Fleming ID, et al., eds. AJCC Cancer Staging Manual, 6th ed. New York, NY: Springer-Verlag; 2002:255–281.
Krishnan C, Moline S, Anders K, Warnke RA. Intravascular ALK-positive anaplastic large cell lymphoma mimicking inflammatory breast cancer. J Clin Oncol 2009;27:2563–2565.
Gruber G, Ciriolo M, Altermatt HJ, et al. Prognosis of dermal lymphatic invasion with or without clinical signs of inflammatory breast cancer. Int J Cancer 2004;109:144–148.
Paradiso A, Tommasi S, Brandi M, et al. Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer 1989;64:1922–1927.
Kleer CG, van Golen KL, Merajver SD. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2000;2:423–429.
Turpin E, Bieche I, Bertheau P, et al. Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene 2002;21:7593–7597.
Gonzalez-Angulo AM, Sneige N, Buzdar AU, et al. p53 expression as a prognostic marker in inflammatory breast cancer. Clin Cancer Res 2004;10(18 Pt 1):6215–6221.
Van Laere SJ, Van den Eynden GG, Van der Auwera, et al. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat 2006;95:243–255.
van Golen KL, Wu ZF, Qiao XT, et al. RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2000;2:418–425.
Kleer CG, Zhang Y, Pan Q, et al. WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene 2002;21:3172–3180.
Singletary SE, Cristofanilli M. Defining the clinical diagnosis of inflammatory breast cancer. Semin Oncol 2008;35:7–10.
Chow CK. Imaging in inflammatory breast carcinoma. Breast Dis 2005;22:45–54.
Yang WT, Le-Petross HT, Macapinlac H, et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat 2008;109:417–426.
Renz DM, Baltzer PA, Bottcher J, et al. Inflammatory breast carcinoma in magnetic resonance imaging: a comparison with locally advanced breast cancer. Acad Radiol 2008;15:209–221.
Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 2007;25:4104–4109.
Wahl RL, Siegel BA, Coleman RE, et al. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET study group. J Clin Oncol 2004;22:277–285.
Baslaim MM, Bakheet SM, Bakheet R, et al. 18-Fluorodeoxyglucose-positron emission tomography in inflammatory breast cancer. World J Surg 2003;27:1099–1104.
Carkaci S, Macapinlac HA, Cristofanilli M, et al. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med 2009;50:231–238.
Panades M, Olivotto IA, Speers CH, et al. Evolving strategies for inflammatory breast cancer: a population-based survival analysis. Clin Oncol 2005;23:1941–1950.
Perez CA, Graham ML, Taylor ME, et al. Management of locally advanced carcinoma of the breast. I. Noninflammatory. Cancer 1994;74(1 Suppl):453–465.
Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460–469.
Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol 1997;40:321–329.
Harris EE, Schultz D, Bertsch H, et al. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 2003;55:1200–1208.
Baldini E, Gardin G, Evangelista G, et al. Long-term results of combined-modality therapy for inflammatory breast carcinoma. Clin Breast Cancer 2004;5:358–363.
Low JA, Berman AW, Steinberg SM, et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 2004;22:4067–4074.
Veyret C, Levy C, Chollet P, et al. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial. Cancer 2006;107:2535–2544.
Cristofanilli M, Buzdar AU, Sneige N, et al. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer 2001;92:1775–1782.
Guerin M, Gabillot M, Mathieu MC, et al. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer 1989;43:201–208.
Lerebours F, Bertheau P, Bieche I, et al. Evidence of chromosome regions and gene involvement in inflammatory breast cancer. Int J Cancer 2002;102:618–622.
Charpin C, Bonnier P, Khouzami A, et al. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR. Anticancer Res 1992;12:591–597.
Sawaki M, Ito Y, Akiyama F, et al. High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer. Breast Cancer 2006;13:172–178.
Parton M, Dowsett M, Ashley S, et al. High incidence of HER-2 positivity in inflammatory breast cancer. Breast 2004;13:97–103.
Prost S, Le MG, Douc-Rasy S, et al. Association of c-erbB2-gene amplification with poor prognosis in non-inflammatory breast carcinomas but not in carcinomas of the inflammatory type. Int J Cancer 1994;58:763–768.
Limentani SA, Brufsky AM, Erban JK, et al. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J Clin Oncol 2007;25:1232–1238.
Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003;21:46–53.
Hurley J, Doliny P, Reis I, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006;24:1831–1838.
Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375:377–384.
Boussen H, Cristofanilli M, Zaks T, et al. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. J Clin Oncol 2010;28:3248–3255.
Van der Auwera I, Van den Eynden GG, Colpaert CG, et al. Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study. Clin Cancer Res 2005;11:7637–7642.
Shirakawa K, Tsuda H, Heike Y, et al. Absence of endothelial cell, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res 2001;61:445–451.
Overmoyer B, Robertson K, Persons M, et al. A phase I pharmokinetic and pharmacodynamic study of SU5416 and doxorubicin (ADR) in inflammatory breast cancer (IBC) [abstract]. J Clin Oncol 2001;20(Suppl 1):Abstract 391.
Wedam S, Low J, Yang X, et al. A pilot study to evaluate response and angiogenesis after treatment with bevacizumab in patients with inflammatory breast cancer [abstract]. J Clin Oncol 2004;21(Suppl 1):Abstract 578.
Sonpavde G, Hutson TE. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 2007;9:115–119.
Johnston SR, Hickish T, Ellis P, et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 2003;21:2492–2499.
Vlastos G, Fornage BD, Mirza NQ, et al. The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy. Am J Surg 2000;179:446–452.
Curcio LD, Rupp E, Williams WL, et al. Beyond palliative mastectomy in inflammatory breast cancer—a reassessment of margin status. Ann Surg Oncol 1999;6:249–254.
Liao Z, Strom EA, Buzdar AU, et al. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Int J Radiat Oncol Biol Phys 2000;47:1191–1200.
Woodward WA, Buchholz TA. The role of locoregional therapy in inflammatory breast cancer. Semin Oncol 2008;35:78–86.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Author(s)

Holly Dushkin, MD

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania

Disclosures

Disclosure: Holly Dushkin, MD, has disclosed no relevant financial relationships.

Massimo Cristofanilli, MD

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania

Disclosures

Disclosure: Massimo Cristofanilli, MD, has disclosed no relevant financial relationships.

Editor(s)

Kerrin M. Green, MA

Assistant Managing Editor, Journal of the National Comprehensive Cancer Network

Disclosures

Disclosure: Kerrin M. Green, MA, has disclosed no relevant financial relationships.

CME Author(s)

Charles P. Vega, MD

Associate Professor; Residency Director, Department of Family Medicine, University of California, Irvine

Disclosures

Disclosure: Charles P. Vega, MD, has disclosed no relevant financial relationships.

CME Reviewer(s)

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Sarah Fleischman

CME Program Manager, Medscape, LLC

Disclosures

Disclosure: Sarah Fleischman has disclosed no relevant financial relationships.

CME

Inflammatory Breast Cancer

Authors: Holly Dushkin, MD; Massimo Cristofanilli, MD
CME Released: 2/7/2011
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 2/7/2012, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for primary care physicians, oncologists, surgeons, radiation oncologists, and other physicians who care for women with IBC.

The goal of this activity is to diagnose and treat IBC appropriately.

Upon completion of this activity, participants will be able to:

Evaluate the epidemiology and clinical presentation of IBC
Distinguish effective imaging modalities in cases of suspected IBC
Analyze effective management strategies for cases of IBC

Disclosures

Author(s)

Holly Dushkin, MD

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania

Disclosures

Disclosure: Holly Dushkin, MD, has disclosed no relevant financial relationships.

Massimo Cristofanilli, MD

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania

Disclosures

Disclosure: Massimo Cristofanilli, MD, has disclosed no relevant financial relationships.

Editor(s)

Kerrin M. Green, MA

Assistant Managing Editor, Journal of the National Comprehensive Cancer Network

Disclosures

Disclosure: Kerrin M. Green, MA, has disclosed no relevant financial relationships.

CME Author(s)

Charles P. Vega, MD

Associate Professor; Residency Director, Department of Family Medicine, University of California, Irvine

Disclosures

Disclosure: Charles P. Vega, MD, has disclosed no relevant financial relationships.

CME Reviewer(s)

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Sarah Fleischman

CME Program Manager, Medscape, LLC

Disclosures

Disclosure: Sarah Fleischman has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and JNCCN - The Journal of the National Comprehensive Cancer Network. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Medscape, LLC designates this Journal-based activity CME for a maximum of 1.00 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape Education encourages you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

processing....

Abstract

Inflammatory breast cancer (IBC) represents the most virulent form of breast cancer, characterized by involvement of the skin and rapid progression of the disease. Management involves careful coordination of multidisciplinary modalities, including imaging, systemic chemotherapy, surgery, and radiation therapy. The use of neoadjuvant chemotherapy has contributed significantly to improvement in overall survival since the first descriptions of this entity, and has made the role of locoregional therapy, including surgery and radiation, critical to continued improvements in this disease. This article examines the unique epidemiology and pathology of IBC, and reviews the various treatment modalities, noting the significance of a multimodality approach and delineating each of the specific components. Moreover, the current research in IBC is briefly described, which experts hope will further improve systemic therapies. (JNCCN 2011;9:233–241)

Page 1 of 8

Overview/Epidemiology

CME Information

References

References

Disclaimer

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on www.medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Table 1.

References

Faculty and Disclosures

Author(s)

Holly Dushkin, MD

Massimo Cristofanilli, MD

Editor(s)

Kerrin M. Green, MA

CME Author(s)

Charles P. Vega, MD

CME Reviewer(s)

Nafeez Zawahir, MD

Sarah Fleischman

CME

Inflammatory Breast Cancer

Target Audience and Goal Statement

Disclosures

Author(s)

Holly Dushkin, MD

Massimo Cristofanilli, MD

Editor(s)

Kerrin M. Green, MA

CME Author(s)

Charles P. Vega, MD

CME Reviewer(s)

Nafeez Zawahir, MD

Sarah Fleischman

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Inflammatory Breast Cancer

Abstract

Table of Contents